甲状腺球蛋白与分化型甲状腺癌

邱忠领; 罗全勇

doi:10.3760/cma.j.issn.1673-4114.2009.02.008

甲状腺球蛋白与分化型甲状腺癌

邱忠领 , 罗全勇

文章导航 > 国际放射医学核医学杂志 > 2009, 33 > 2: (89-92)

引用本文:

Citation:

甲状腺球蛋白与分化型甲状腺癌

上海交通大学附属第六人民医院核医学科, 上海 200233

Thyroglobulin and differentiated thyroid cancer

Department of Nuclear Medicine, The Sixth People's Hospital, Shanghai JiaoTang University, Shanghai 200233, China

摘要: 甲状腺球蛋白(Tg)检测对分化型甲状腺癌(DTC)的诊治具有重要价值,尽管其测量受诸多因素影响,但手术及¹³¹I清除残留甲状腺后,Tg仍是监测DTC复发或转移的一项灵敏而又特异的肿瘤标志物.Tg检测与¹³¹I扫描的价值互为补充.此外,Tg免疫组化分析、Tg mRNA及Tg抗体等在DTC的诊治与随访中也具有一定价值.
- 甲状腺球蛋白 /
- 甲状腺肿瘤
Abstract: Thyroglobulin(Tg) measurements play an important role in the management of differentiated thyroid carcinoma(DTC).Tg is a highly specific and sensitive tumor marker for detection of recurrence and metastasis of DTC.Tg assays and radioiodine scans are complementary.Immunohistochemical detection of Tg,Tg mRNA and thyroglobulin antibody(TgAb) also play important roles in the management of DTC.
- Thyroglobulin /
- Thyroid neoplasms
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	De Felice M, Di Lauro R. Thyroid development and its disorders:genetics and molecular mechanisms. Endocr Rev, 2004, 25(5):722-746.
[2]	Eustatia-Rutten CF, Smit JW, Romijn JA, et al. Diagnostic value of thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol (Oxf), 2004, 61(1):61-74.
[3]	Whitley Pal, Ain KB. Thyroglobuhn:a specific serum marker for the management of thyroid carcinoma. Clin Lab Med, 2004, 24(1):29-47.
[4]	Feldt-Rasmussen U, Schlumberger M. European interlaboratory comparison of serum thyroglobulin measurement. J Endocrinol Invest, 1988, 11(3):175-151.
[5]	Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for lowrisk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab, 2003, 88(4):1433-1441.
[6]	Pellegriti G, Scollo C, Regalbuto C, et al. The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels. Clin Endoerinol (Off), 2003, 58(5):556-561.
[7]	Ehom A, Elnagar B, Elbagir M, et al. Thymoglobulin in serum as an indicator of iodine status during pregnancy. Scand J Clin Lab Invest, 2000, 60(1):1-7.
[8]	Wagner K, Arciaga R, Siperstein A, et al. Thyrotropin receptor/thyroglobulin messenger ribonucleic acid in peripheral blood and fine-needle aspiration cytology:diagnostic synergy for detecting thyroid cancer. J Clin Endocrinol Metab, 2005, 90(4):1921-1924.
[9]	Bellantone R, Lombardi CP, Bossola M, et al. Validity of thyroglobulin mRNA assay in peripheral blood of postoperative thyroid carcinoma patients in predicting tumor recurrences varies according to the histologic type:results of a prospective study. Cancer, 2001, 92(9):2273-2279.
[10]	Karavitaki N, Lembessis P, Tzanela M, et al. Molecular staging using qualitative RT-PCR analysis detecting thyreoglobulin mRNA in the peripheral blood of patients with differentiated thyroid cancer after therapy. Anticancer Res, 2005, 25(4):3135-3142.
[11]	Chinnappa P, Taguba L, Arciaga R, et al. Detection of thyralropinreceptor messenger ribonucleic acid (mRNA) and thyroglobulin mRNA transcripts in peripheral blood of patients with thyroid disease:sensitive and specific markers for thyroid cancer. J Clin Endocrinol Metab, 2004, 89(8):3705-3709.
[12]	Elisei R, Vivaldi A, Agate L, et al. Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow-up of differentiated thyroid cancer patients. J Clin Endocrinol Metab, 2004, 89(1):53-39.
[13]	Shlossberg AH, Jacobson JC, Ibbertson HK. Serum thyroglobulin in the diagnosis and management of thyroid carcinoma. Clin Endoerinol (0xf), 1979, 10(1):17-27.
[14]	Heemstra KA, Liu YY, Stokkel M, et al. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clin Endocrino (0xf), 2007, 66(1):58-64.
[15]	Hishinuma A, Fukata S, Kakudo K, et al. High incidence of thyroid cancer in long-standing goiters with thyroglobulin mutations. Thyroid, 2005, 15(9):1079-1084.
[16]	Baloch Z, Carayon P, Conte-Devolx B, et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid, 2003, 13(1):3.

[1]	惠金子 , 赵德善 . Tg、TgAb及TSH在分化型甲状腺癌术前的预测分析. 国际放射医学核医学杂志, 2015, 39(2): 110-115. doi: 10.3760/cma.j.issn.1673-4114.2015.02.002
[2]	林军 , 缪蔚冰 , 吴立坚 , 汤冰 . ¹³¹I治疗分化型甲状腺癌转移灶中甲状腺球蛋白测定和¹³¹I-全身显像的意义. 国际放射医学核医学杂志, 2006, 30(3): 161-162,167.
[3]	侯莎莎 , 沈婕 , 秦岚 . ¹³¹I全身显像及血清甲状腺球蛋白测定在分化型甲状腺癌治疗随访中的作用. 国际放射医学核医学杂志, 2013, 37(5): 269-271. doi: 10.3760/cma.j.issn.1673-4114.2013.05.004
[4]	高刘艳 , 李素平 . 甲状腺球蛋白和甲状腺球蛋白抗体在分化型甲状腺癌诊治中的价值. 国际放射医学核医学杂志, 2020, 44(3): 196-201. doi: 10.3760/cma.j.cn121381-201812053-00009
[5]	龙再颖 , 汤春静 , 于立明 , 赵燕霞 , 单英丽 , 赵旭龙 . 甲状腺乳头状癌术后刺激状态Tg与颈部淋巴结转移关系的研究. 国际放射医学核医学杂志, 2013, 37(1): 27-29. doi: 10.3760/cma.j.issn.1673-4114.2013.01.008
[6]	胡斌 , 王锦锋 , 毛秋粉 . ¹⁸F-FDG PET/CT显像在Tg阳性¹³¹I全身显像阴性的分化型甲状腺癌患者中的应用价值. 国际放射医学核医学杂志, 2015, 39(3): 242-246, 251. doi: 10.3760/cma.j.issn.1673-4114.2015.03.012
[7]	丁颖 , 李文亮 , 李强 , 李德宇 , 张富强 , 丁献敏 , 王丽君 , 陈鸿彪 , 贾建敏 , 杨辉 . 分化型甲状腺癌术后首次血清刺激性Tg水平对远处转移的预测价值. 国际放射医学核医学杂志, 2019, 43(4): 308-313. doi: 10.3760/cma.j.issn.1673-4114.2019.04.003
[8]	赵腾 , 梁军 , 林岩松 . ¹³¹I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义. 国际放射医学核医学杂志, 2015, 39(1): 61-66. doi: 10.3760/cma.j.issn.1673-4114.2015.01.013
[9]	赵腾 , 梁军 , 林岩松 . ¹³¹I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义. 国际放射医学核医学杂志, 2015, 39(1): 61-66.
[10]	咸雨蔚 , 左书耀 . 甲状腺肿瘤SPECT-CT融合显像的应用近况. 国际放射医学核医学杂志, 2006, 30(3): 157-160.

点击查看大图

计量

文章访问数: 1759
HTML全文浏览量: 298
PDF下载量: 4

甲状腺球蛋白与分化型甲状腺癌

上海交通大学附属第六人民医院核医学科, 上海 200233

收稿日期: 2008-12-19

关键词:

甲状腺球蛋白 /
甲状腺肿瘤

摘要: 甲状腺球蛋白(Tg)检测对分化型甲状腺癌(DTC)的诊治具有重要价值,尽管其测量受诸多因素影响,但手术及¹³¹I清除残留甲状腺后,Tg仍是监测DTC复发或转移的一项灵敏而又特异的肿瘤标志物.Tg检测与¹³¹I扫描的价值互为补充.此外,Tg免疫组化分析、Tg mRNA及Tg抗体等在DTC的诊治与随访中也具有一定价值.